43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction

Publication
Article
Miami Breast Cancer Conference® Abstracts Supplement41st Annual Miami Breast Cancer Conference® - Abstracts
Volume 38
Issue 4
Pages: 49-51

Background

The Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) is a prophylactic microsurgical technique performed at the time of axillary lymph node dissection (ALND) that reduces the rate of developing lymphedema (LE). It is often performed together with immediate implant-based breast reconstruction (IBBR) in patients undergoing mastectomy with ALND. This study aimed to determine whether the additional LYMPHA procedure impacts the surgical outcomes of mastectomy with IBBR.

Methods

Patient Characteristics Across Various Subgroups

Patient Characteristics Across Various Subgroups

A retrospective cohort study included patients with breast cancer undergoing mastectomy with IBBR (tissue expander [TE] or implant) with and without ALND with LYMPHA between April 2021 and August 2023 at a single institution. Patient demographics, treatment characteristics, and complication rates were collected. The complications evaluated included hematoma, seroma, minor infection (resolved with oral antibiotics), major infection (need for intravenous antibiotics), wound dehiscence, mastectomy flap necrosis, implant/AlloDerm exposure, and readmission within 90 days of surgery. The primary outcome was a comparison of the rate of complications within 90 days of surgery in patients with and without ALND and LYMPHA.

Results

Patient Characteristics Across Various Subgroups (cont.)

Patient Characteristics Across Various Subgroups (cont.)

Of 94 patients with mastectomy followed by IBBR, 54.3% (n = 51) had no ALND and LYMPHA, and 45.7% (n = 43) had an ALND and LYMPHA. All baseline demographic features were evenly distributed between both cohorts. Patients with a higher-stage breast cancer requiring neoadjuvant chemotherapy were more likely to be present in the ALND with LYMPHA cohort (P < .001). Mastectomy types, implant types, and laterality of surgery were evenly distributed. ALND with LYMPHA had a longer anesthesia time (417.5 vs 513.9 minutes; P < .001). There was no hematoma in either cohort. Seroma occurred in 7.84% of patients of the non-LYMPHA cohort and 16.28% of those who underwent IBBR with LYMPHA (P = .205). Major infection rates were 5.88% in patients without LYMPHA and 6.98% in those with LYMPHA (P = .829). Minor infections were seen in none without LYMPHA and 6.98% of patients with LYMPHA (P = .05). Wound dehiscence occurred in 1.96% without LYMPHA and 2.33% with LYMPHA (P = .9). Mastectomy flap edge necrosis occurred in no patients without LYMPHA and 6.98% with LYMPHA (P = .05). One patient had implant removal because of AlloDerm exposure in the LYMPHA cohort. In all, 5.88% and 6.98% had complication-related hospital readmission within 90 days of surgery in the non-LYMPHA and LYMPHA cohorts, respectively (P = .829). There were no statistically significant differences in the individual complication rates with multivariate analysis, as well as on controlling for body mass index, cancer stage, chemotherapy, and anesthesia time. Overall complication rates had no statistically significant difference (13.73% vs 27.91%; P = .09).

Conclusions

ALND with LYMPHA had no statistically significant differences in complication rates as compared to no ALND and LYMPHA. LYMPHA should be performed with ALND to reduce LE, as it does not increase the risk of postoperative complications.

Articles in this issue

31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
31 Adjuvant Abemaciclib Plus Endocrine Therapy for HR+, HER2–, High-Risk Early Breast Cancer: Results From a Preplanned MonarchE Overall Survival Interim Analysis, Including 5-Year Efficacy Outcomes
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
32 Neoadjuvant Pembrolizumab or Placebo Plus Chemotherapy Followed by Adjuvant Pembrolizumab or Placebo for Early-Stage Triple- Negative Breast Cancer: Updated Event-Free Survival Results From the Phase 3 KEYNOTE-522 Study
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
33 MammaPrint® and BluePrint® Predict Anthracycline Chemosensitivity in Patients With HR+HER2– Early-Stage Breast Cancer Enrolled in FLEX
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
34 How Mobile Computing Devices Offer Support for Classic and Molecular Multidisciplinary and Tumor Boards
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
35 Impact of Comorbidities on Real-World (rw) Clinical Outcomes of Patients (pts) With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2–Negative (HR+/HER2–) Advanced Breast Cancer (ABC) Treated With Palbociclib (PAL) and Enrolled in POLARIS
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
36 MONARCH 3: Final Overall Survival Results of Abemaciclib Plus a Nonsteroidal Aromatase Inhibitor as First-Line Therapy for HR+/HER2– Advanced Breast Cancer
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
37 Estimating the Direct and Indirect Resource Burden of Treatment Management With Current Standard of Care or Elacestrant for ER+, HER2–, ESR1-Mutated Advanced or Metastatic Breast Cancer Patients: A Population- Level Provider Model
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
38 Influence of Race on Attainment of Textbook Oncologic Outcome Following Modified Radical Mastectomy for Breast Cancer
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction:  A Nationwide Study
39 The Influence of Reconstruction Type on Outcomes in Women Undergoing Mastectomy With Immediate Reconstruction: A Nationwide Study
40 Ethnic Disparities in Complication Rates and Outcomes  of Nipple-Sparing Mastectomy:  A Comprehensive Analysis
40 Ethnic Disparities in Complication Rates and Outcomes of Nipple-Sparing Mastectomy: A Comprehensive Analysis
41 A Case Series of Sarcomas
41 A Case Series of Sarcomas
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
42 Transitional Lymphedema: Understanding the Temporal Dynamics Post-Axillary Surgery
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
43 Impact of Lymphatic Microsurgical Preventing Healing Approach (LYMPHA) on Postoperative Complication Rates in Mastectomy With Immediate Prosthetic-Based Breast Reconstruction
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
44 Variant of Uncertain Significance (VUS) Genetic Testing Results and Mastectomy Choice in Lumpectomy-Eligible Patients
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
45 Application of the 7-Gene Biosignature in Palpable Versus Nonpalpable Ductal Carcinoma In Situ in a Black Patient Population: Does Palpability Suggest a More Aggressive Genomic Risk?
Related Videos
Paolo Tarantino, MD, discusses the potential utility of agents such as datopotamab deruxtecan and enfortumab vedotin in patients with breast cancer.
Paolo Tarantino, MD, highlights strategies related to screening and multidisciplinary collaboration for managing ILD in patients who receive T-DXd.
Pegulicianine-guided breast cancer surgery may allow practices to de-escalate subsequent radiotherapy, says Barbara Smith, MD, PhD.
Barbara Smith, MD, PhD, spoke about the potential use of pegulicianine-guided breast cancer surgery based on reports from the phase 3 INSITE trial.
Carey Anders, MD, an expert on breast cancer
Related Content